| Peer-Reviewed

A New Hypothesis of Duchenne Muscular Dystrophy

Received: 24 November 2020     Accepted: 9 December 2020     Published: 13 April 2021
Views:       Downloads:
Abstract

Duchenne Muscular Dystrophy is the product the mutation the gene-dystrophine and appearing defective protein dystropnin. Its function is unclear, suppose protection membranes during the contraction-relax skeletal muscles. The cytoplasmic dystrophin acts as the complexes with different proteins inside and around membranes, which are placing in skeletal muscls, heart, different regions brain, internal organs, their function unclear. The high activity enzyme creatin-kinasa in the patients blood is the known fact which is usually explain damage of the process contraction-relax skeletal muscles. The surprising activity enzyme -23 000 M E was found by author at large families with typical pedigree where have some patients and some boys without signs muscle weakness. There were 4 boys 12-22 months life during forming walk, later these boys were diagnosed as Duchenne Muscular Dystrophy patients. Such activity I did not find in literature. Usually the highest activity enzyme 10 000-12 000 ME. This fact testify the simultaneously damage many membranes on large territory, it permits suppose organized damage membranes. Author believe all complexes normal dystrophines may work as one System, beginning learn walk and finishing as age myopathy after 60 years. Suppose the System was ancient and appeared when movements become intensive and one gene utrophine/dystrophine turned out in two genes: utrophin and dystrophin. Dystrophin signal communication is known, but its investigation has begun and showed complex signaling pathways. It is possible to suppose that the first stage of the disease is damage signaling ways. Damage homeostasis and membranes is the second stage. There are deep changes of metabolism: decreasing true muscle proteins, phospholipids, increasing hormones, appearing hyper aminoaciduria. Apoptosis –the three stage of the disease and general destructive factor which turn out pathologic process to the fatal end. Apoptosis hinder all tryings organism to interrupt pathological process and therapeutic trying. Apoptosis can not stop once it began. All three stages have place in preclinical time. The clinic symptoms express destruction more the half skeletal muscles, severe damage metabolism, damage system protection membranes and can not be onset of the disease. The important problem of the disease – studying interaction dystrophin-complexes with membranes during physical stress, signaling ways. Two factors determinate rapid course: damage D-System and apoptosis.

Published in American Journal of Psychiatry and Neuroscience (Volume 9, Issue 2)
DOI 10.11648/j.ajpn.20210902.11
Page(s) 25-30
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Dystrophin, Creatinkinasa, Phospholipids, Apoptosis

References
[1] Kunkel L. et al. Analysis of deletions in DNA from patients with Becker and Duchenn Muscular Dystrophy. Nature 1986, 322, 73.
[2] Furakawa T., Peter. The Muscular Dystrophy and related disorder. JAMA 1978, 239, 1654-1659.
[3] Emery A., The Muscular Dystrophy. Lancet. 2002, 359, 687695.
[4] Hoffmann E., Brown R, Kunkel L. Dystrophin: protein product of Duchenne muscular dystrophy. Cell, 1987, 51, 919-928.
[5] –Кoenig M. Kunkel L/ detailed analysis of the rapid domainof dystrophin reveals four potentialhinge segmsnts that may confer flexibility J/Biol. Chem. 1990, 265, 8. 4560-4566.
[6] Rumeir E. Winder S. Hubert J. Dystrophin. 2012 FEBS Lett. 586, 2717-2719.
[7] Blake D., Weir A. Newey S. Davies K. Function and genetics of dystrophin and dystrophin-related proteins in muscles. Physiological Rewiews 2002, 82, 2291-3.
[8] Lidov H., Byers T., Kunkel L., The distribution of dystrophin in the murine central nervous system cortical neurons. Nature. 1990, 348, 72-8.
[9] Goldstein J., Mc Nally E., Mechanism of muscle weakness in muscular dystrophy. Archive 2010, 136, 1-29.
[10] Rubakova I., Humston J., SonnemannK., Ervasti J. Dystriophin and Utrophin Bind Actin trough distinct modes of contact., J. Biol. Chem. 2006, 281, 15, 9996-10001.
[11] Piluso G., Aurino S., Veechio B., NigroV., Mendelian bases of myopathies, cardiomyopathies and neuromyopathies. Acta Myologica. 2010, 29, 1-20.
[12] Piluso G., Mirabella M., ei al. Gammal-and gamma 2-syntropins, two novel dystrophin-binding proteins localized in neuronall cells. J. Biol. Chem., 2000., 275., 15851-158860.
[13] Van Putten, Kumar D., Van Ommen., Functional and pathological comparison of mouse-models for Duchenne Muscular Dystrophy. Acta Myologica. 2010, 29, 138-139.
[14] Zhong J et al. Genetic analysis of the D –gene in children with DMD and Becker muscular dystrophy., Muscle, Nerve, 2017 56, 11, 117-1214.
[15] Sekiguchi M., Zushida K., et al. A deficit of brain dystrophin impairs specific amygdala GABA ergictransmission and enhances defensive behavior in mice. Brain, 2008., 10.
[16] Goodnough C., Ying Gao. Lack of dystrophin results in abnormal cerebral diffusion and perfusion in vivo disrubtion of blood-barrer. Neurolmage 2014. 102, 2 809-816.
[17] Godfrey C., Muses S., et al.,. How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouses. Hum. Mol. Genet. 2015, 1, 24. 4225-37.
[18] Gee S. Madhavan R. Lesinson S. et al. Interaction of Muscle and brain sodium channels with multiple members of the syntropin family of dystrophin associated proteins. J. Neuroscience 1998, 18, 1, 128-127.
[19] Niels B., Takedo S., Yokota T. Nonmechanical rols of Dystrophin and associated proteins in exercise neuromuscular junctions and brain Brain Sci, 2015. 5. 275-298.
[20] Sojos V., Curto M., Reali C., GremoF., Developmentally regulated expression and localization of dystrophin and utropin in the human fetal brain. Mech Ageing Dev. 2002, 123, 5, 455-62.
[21] Koenig X., Ebner J., Hilber K., Voltage-dependent sarcolemmal ione channels abnormalities J. Mol. Sci. 2018, 19, 11, 3296.
[22] van Putten M., van Pul, Hulsker M., Low dystrophin levels in heart can delay heart failure in mdx mice. J, Mol. Cellul. Cardiology 2014, 1, 009.
[23] Wickell R., Kihlgren M., et al. Specific cognitive deficits are common in children with Duchenne Muscular Dystrophy. Dev. Child. Neurol 2004, 46, 154-9.
[24] Hendriksen R., Schipper S., Hoogland G., Dystrophin distribution and expression in human. 2016. Cell Neuroscience, 2, 00174.
[25] Waite A., Blake D., Brown S., The dystrophin –glucoprotein complex in brain development and disease. Neurosciences 2012, 35, 8, 497-96.
[26] Deisch J. Swasman P. Development in Health and Disease. Pediatric Neurology. 2017, 6, 1029-310.
[27] KimT, W, Wu, K., Black Defiency in brain sinaptic dystrophin in human Duchenne Muscular Dystrophy. Ann. Neurol. 1995, 38, (3) 446-49.
[28] Culligan K., Glover L., Dowling P. Brain dystrophin-glucoprotein complex persistent expression of B-dystroglucan impaired oligolregulation of Dp71 and up-regulation of utropin in animal models. Cell Biology 2991.
[29] Brown S., Lucy J., “Dystrophin”. 1991. Cambridge University Press.
[30] Darras B., Kunkel L., “Dystrophinopathies” in Neuromuscular Disorder of Infancy. 2011 chapter 107, 684-697.
[31] Haenggi T., Fritschy J., Role of Dystrophin and utropin for assembly and function of the dystrophin glucoprotein complex in non-muscle tissue. Cell. Mol. Life Sciences 2006, 69, 14, 1614-3.
[32] Grinio L.,. Duchenne Myodystrophy. Russ. monografy pub. НГМА, 1998, 1-100.
[33] Grinio L., Pathogenesis of Duchenne Muscular Dystrophy. Russ. J. Neurol. Psych. 2019, 1 19, 3, 79-81.
[34] Escolar D., Leshner R., Treatment and management of Muscular Dystrophy. In “Neuromuscular Disorder of Infancy”. 2011, 343-372.
[35] Kogelman B,., Khmelinski A., Verhaat I. Influence of full-length dystrophin on brain volumes in mouse models of Duchenne Mudcular Dystrophy. 2018 http^ 11 org/10. 1371/journal pone 0104636.
[36] Nicols B. Takeda S. Yokota T. Nonmechanical roles of Dystrophin and associated proteins in exercise Brain. Sci. 2015, 5, 275-281.
[37] Dreyfus J. Shapira G. Biochemisytry of hereditary of Myopathies. 1963, 1-14.
[38] Daoud F., Candelario-Martinez A., Role of mental retardation associated dystrophin-gene product Dp71 in excitatory synapse organization synaptic organization, synaptic plasticity and behavioral functions. PLOS One 2009, 4, 8, 6.
[39] Bresolini N., Castelli E., Comi G. et al. Cognitive impairment in Duchenne Muscular Dystrophy. Neuromusculat Disorder, 1994, 4, 359-69.
[40] Fitzpatrik C., Barry C., Garvey C., Psychiatric disorder among boys with Duchenne Muscular Dystrophy. Dev. Med. Child Neurology. 1986, 399, 194-210.
[41] Anderson J., Heads S., Roe E., Morley J., Brain function in Duchenne Musular Dystrophy., Brain, 2002, 125, 4-13.
[42] Tracey I., Dunn J., Radda G., Brain metabolism is abnormal in the mdx model of DMD., Brain., 1996., 119., 1039-44. 9. Wicksell R., Kihlgren M et al. Specific cognitive deficits are common in children with Duchenne Muscular Dystrophy. Dev. Med. Child Neurol. 2004, 46, 154-9.
[43] Nigro V., Okozaki Y. ei al. Identification of the Syrian hamster cardiomyopathy gene. Hum. MoL. Genet. 1997, 6, 601-07.
[44] Sekiguochi M., Zushide., K., Yoshida M. A deficit of brain dystrophin impairs specific amygdala GABAergic transmission and enhances defensive behavior in mice. Brain 2009, 132, 1, 124-135.
[45] Aleman V., Osorio B., Chavez, O., Subcellular localization of Dp71 dystrophin isoforms in cultured hippocampal neurons and forebrain astrocytes. Histochemistry and Cell Biology 2007, 115, 3, 243-2526.
[46] Anderson J., Head S., Morley J., Long-term depression is reduced in cerebellarar Purkinje cells of dystrophin-deficient mdx mice. Brain. Research 2009. 19, 1-2, 289292.
[47] Banks. G., Gregorevic P., Allen J., Finn E. Chamberlain J. Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain. Human Molecular Genetics 2007, 16 (17), 2105-2113231.
[48] Abatado J. Apoptosis, function and regulation of cell death. Res. Immunol. 1996, 147, 443-456.
[49] Savitz S., Daniel B., Rosenbaum M., Apoptosis in neurological siseases., Neurosurgery 1998, 42, 555-72.
[50] Arends M. Wyllie A., Apoptosis, Mechanism and role in pathology 11 Int. Rev. Exp. Pathol. 1991, 32, 223-2.
[51] Tang H. Cell survival DNA damage and oncogenic transformation after a transiet and reversible response. Mol. Biol. Cell 2012, 23, 2940-52.
[52] Borras G. Programmed cell death in plants and animals. Biotechnologia Aplicada. 2006, 23, 1-10.
[53] Morikawa Y., Heallen T., Leach J., Xiao Y., Morton J. Dyst-glucoprotein complex sequesters to inhibid cardiomyocyte proliferation. Nature 2017. 13, 547, 227-231 62., Soyos V., Curto M., Reali C., Grenio F. Developmentally regulated expression and localization of dystrophin and utropin in the human fetal brain. Mech. Ageing Dev. 2002, 123, 5, 455-62.
[54] Milad. N., White Z., Tehrani A., Rossi F., Increased plasma lipid levels in the mdx model. Nature 2017. 13, 547, 227-231.
[55] Goodnough c., Gao Y,. Qutaish Q., Lack dystrophin results in abnormal cerebral diffusion and perfusion in vivo., Neuromage 2014, 192, 2, 809-816.
[56] Brown S., Lucy J.,. Expression D-complex in brain. In book Dystrophin 1997, 13, 1-100.
[57] Tompkins A., Muscle Physiology and Patholoy of Muscular Dystrophy 2010 Everglades University Biology.
[58] Kobayshi Y., Camplell K. The mechanistic basis of maintaining muscle membrane integrity. Muscle Nerve 2012.
[59] Ujihara Y., et al. Elimination of fukutin reveals cellular and molecular pathomechanizms in muscular dystrophy- accociated heart failure. Nature. Communications 2020, 10, 1038-40.
[60] Santos R. New variants challenges and pitfalls in Duchenne Muscular dystrophy genotyping, implications in diagnoses, prognosis and therapy. J. Human Genet. 2014, 59, 454-454.
[61] Luke M., Haraguchiln M, Chamberland S. Dissecting and signaling and mechanical function of the dystrophin in muscular mechanisms of muscular dystrophy. JCellScience 2006, 118, 1537-46.
[62] Thomas G., Sander M., Lau K., HuangP., Impaired metabolic modification of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscles. Proc. Natl. Acad. Sci. 1998, 95, 554-560.
[63] Hoffman E. New research increases understanding of Duchenne Muscular Dystrophy. Amr. J. Human Genet. 2016, 8, 23-28.
[64] Constantin B., Dystrophin complex function as a scaffold for signalic proteins. Biochem et Biophy/s. Acta (BBA) Biomembranes. 2014, 1838, 2, 625.
[65] Brown S., Dystrophin and Utrophin. Genetic analysis of their role in skeletal muscles. Microse. Res. Tech. 2000, 48, 3-4, 155-61.
[66] Judge L., Haraguehiln M., Chamberlain S., Dissecting the signaling and mechanical functions of DGC J. Cell SCI. 2006 15, 119, 1537-46.
[67] Rondo T. A. The dystrophin-glucoprotein complex cellular signaling and regulation of cell survival in the muscular dystrophy. Muscle. Nerve 2001, 24, 1575-159.
[68] Gambardelle A. Dystrophin distribution and expression in human and experimental temporal lobe. Epilepsy Research University Catanzago., 2019. 153. 49-58.
[69] Culligan K., Beta-Dystrobrevin and Dystrophin in brain neurons. Cell Biology 2001, 2, 2-10.
[70] Goldstein J,. Mc Nally E. Mechanism of musle weakness in muscular dystrophy Archive 2010, 136, 1-129.
[71] Ujhara Y. Estimation of fukutin reveals cellular and molecular pathomechanims in muscular dystrophy. Nature 2020, 10, 1038-41.
[72] Vican S., Piccini G., Mercuri E,. Alfieri P. Implacit learnig deficit in children with Duchenne Muscular Dystrophy: evidence for a cerebellar cognitive impairtment Nature 2018 10, 82.
[73] Pins A., Spitali P., Circulating biomarkers for Duchenne Muscular Dystrophy. J. Neuromuscular Disord 2015, 2, 4958.
[74] Allen D., Whitehead N,. Frochner S., Absence of Dystrophin disrubtion skeletal muscle signaling: roles of Ca2, reactive oxygen species, nitric oxide in the development of muscular dystrophy. Physical Rew. 2016, 96, 253-305. 9975Guiraud S.
[75] Davies K. Regenerative biomarkers for Duchenne Muscular Dystrophy. Neural. Regen Res. 2019, 14, 8, 1317-1320.
[76] Grounds M., Ferrill J., Al-Mehdani B., Duong M. Biomarkers for Duchenne Muscular Dystrophy: myonecrosis, inflammation, and oxidative stress. Dis. Model. Mech. 2020, 2, 13, 1242.
[77] Morikawa Y., Heallen T., Leach J. Xiao Y. Martin J. Dyst-glucoprotein Complex sequesters Yap to in cardiomyocytes. Nature 2017, 13, 547, 227-231.
Cite This Article
  • APA Style

    Leonora Grinio. (2021). A New Hypothesis of Duchenne Muscular Dystrophy. American Journal of Psychiatry and Neuroscience, 9(2), 25-30. https://doi.org/10.11648/j.ajpn.20210902.11

    Copy | Download

    ACS Style

    Leonora Grinio. A New Hypothesis of Duchenne Muscular Dystrophy. Am. J. Psychiatry Neurosci. 2021, 9(2), 25-30. doi: 10.11648/j.ajpn.20210902.11

    Copy | Download

    AMA Style

    Leonora Grinio. A New Hypothesis of Duchenne Muscular Dystrophy. Am J Psychiatry Neurosci. 2021;9(2):25-30. doi: 10.11648/j.ajpn.20210902.11

    Copy | Download

  • @article{10.11648/j.ajpn.20210902.11,
      author = {Leonora Grinio},
      title = {A New Hypothesis of Duchenne Muscular Dystrophy},
      journal = {American Journal of Psychiatry and Neuroscience},
      volume = {9},
      number = {2},
      pages = {25-30},
      doi = {10.11648/j.ajpn.20210902.11},
      url = {https://doi.org/10.11648/j.ajpn.20210902.11},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajpn.20210902.11},
      abstract = {Duchenne Muscular Dystrophy is the product the mutation the gene-dystrophine and appearing defective protein dystropnin. Its function is unclear, suppose protection membranes during the contraction-relax skeletal muscles. The cytoplasmic dystrophin acts as the complexes with different proteins inside and around membranes, which are placing in skeletal muscls, heart, different regions brain, internal organs, their function unclear. The high activity enzyme creatin-kinasa in the patients blood is the known fact which is usually explain damage of the process contraction-relax skeletal muscles. The surprising activity enzyme -23 000 M E was found by author at large families with typical pedigree where have some patients and some boys without signs muscle weakness. There were 4 boys 12-22 months life during forming walk, later these boys were diagnosed as Duchenne Muscular Dystrophy patients. Such activity I did not find in literature. Usually the highest activity enzyme 10 000-12 000 ME. This fact testify the simultaneously damage many membranes on large territory, it permits suppose organized damage membranes. Author believe all complexes normal dystrophines may work as one System, beginning learn walk and finishing as age myopathy after 60 years. Suppose the System was ancient and appeared when movements become intensive and one gene utrophine/dystrophine turned out in two genes: utrophin and dystrophin. Dystrophin signal communication is known, but its investigation has begun and showed complex signaling pathways. It is possible to suppose that the first stage of the disease is damage signaling ways. Damage homeostasis and membranes is the second stage. There are deep changes of metabolism: decreasing true muscle proteins, phospholipids, increasing hormones, appearing hyper aminoaciduria. Apoptosis –the three stage of the disease and general destructive factor which turn out pathologic process to the fatal end. Apoptosis hinder all tryings organism to interrupt pathological process and therapeutic trying. Apoptosis can not stop once it began. All three stages have place in preclinical time. The clinic symptoms express destruction more the half skeletal muscles, severe damage metabolism, damage system protection membranes and can not be onset of the disease. The important problem of the disease – studying interaction dystrophin-complexes with membranes during physical stress, signaling ways. Two factors determinate rapid course: damage D-System and apoptosis.},
     year = {2021}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - A New Hypothesis of Duchenne Muscular Dystrophy
    AU  - Leonora Grinio
    Y1  - 2021/04/13
    PY  - 2021
    N1  - https://doi.org/10.11648/j.ajpn.20210902.11
    DO  - 10.11648/j.ajpn.20210902.11
    T2  - American Journal of Psychiatry and Neuroscience
    JF  - American Journal of Psychiatry and Neuroscience
    JO  - American Journal of Psychiatry and Neuroscience
    SP  - 25
    EP  - 30
    PB  - Science Publishing Group
    SN  - 2330-426X
    UR  - https://doi.org/10.11648/j.ajpn.20210902.11
    AB  - Duchenne Muscular Dystrophy is the product the mutation the gene-dystrophine and appearing defective protein dystropnin. Its function is unclear, suppose protection membranes during the contraction-relax skeletal muscles. The cytoplasmic dystrophin acts as the complexes with different proteins inside and around membranes, which are placing in skeletal muscls, heart, different regions brain, internal organs, their function unclear. The high activity enzyme creatin-kinasa in the patients blood is the known fact which is usually explain damage of the process contraction-relax skeletal muscles. The surprising activity enzyme -23 000 M E was found by author at large families with typical pedigree where have some patients and some boys without signs muscle weakness. There were 4 boys 12-22 months life during forming walk, later these boys were diagnosed as Duchenne Muscular Dystrophy patients. Such activity I did not find in literature. Usually the highest activity enzyme 10 000-12 000 ME. This fact testify the simultaneously damage many membranes on large territory, it permits suppose organized damage membranes. Author believe all complexes normal dystrophines may work as one System, beginning learn walk and finishing as age myopathy after 60 years. Suppose the System was ancient and appeared when movements become intensive and one gene utrophine/dystrophine turned out in two genes: utrophin and dystrophin. Dystrophin signal communication is known, but its investigation has begun and showed complex signaling pathways. It is possible to suppose that the first stage of the disease is damage signaling ways. Damage homeostasis and membranes is the second stage. There are deep changes of metabolism: decreasing true muscle proteins, phospholipids, increasing hormones, appearing hyper aminoaciduria. Apoptosis –the three stage of the disease and general destructive factor which turn out pathologic process to the fatal end. Apoptosis hinder all tryings organism to interrupt pathological process and therapeutic trying. Apoptosis can not stop once it began. All three stages have place in preclinical time. The clinic symptoms express destruction more the half skeletal muscles, severe damage metabolism, damage system protection membranes and can not be onset of the disease. The important problem of the disease – studying interaction dystrophin-complexes with membranes during physical stress, signaling ways. Two factors determinate rapid course: damage D-System and apoptosis.
    VL  - 9
    IS  - 2
    ER  - 

    Copy | Download

Author Information
  • Department Ministry Health, Moscow University Medicine and Dentistry, Moscow, Russia

  • Sections